Arvinas, Inc. (Nasdaq: ARVN), announced that the U.S. Food and Drug Administration (FDA) has granted approval for VEPPANU (vepdegestrant, ARV-471) for the treatment of adults with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer. PROTACs are bifunctional molecules that bind to the target protein and […]